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Abstract
Phase I trials evaluating the safety of multi-drug combinations are becoming more common in 
oncology. Despite the emergence of novel methodology in the area, it is rare that innovative 
approaches are used in practice. In this article, we review three methods for Phase I combination 
studies that are easy to understand and straightforward to implement. We demonstrate the 
operating characteristics of the designs through illustration in a single trial, as well as through 
extensive simulation studies, with the aim of increasing the use of novel approaches in phase I 
combination studies. Design specifications and software capabilities are also discussed.
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1 Introduction
In oncology drug development, there has been an increasing interest in investigating the 
potential of drug combinations for patient treatment. The motivation to treat with drug 
combinations stems from the desire to improve the response of the patient, especially those 
who have been resistant to traditional treatment. Multi-agent dose-finding trials present the 
significant challenge of finding a MTD combination (MTDC), or combinations, of the 
agents being tested with the typically small sample sizes involved in phase I studies. Many 
authors have developed dose-finding methods for drug combinations, a thorough review of 
which is given in Harrington et al. (2013). Despite the developments of new methods in the 
area, a recent literature review revealed that the use of novel methods in practice is quite 
limited (Riviere et al., 2015). A recent editorial in Journal of Clinical Oncology by 
Mandrekar (2014) described the use of the method of Ivanova and Wang (2004) in a Phase I 
study of neratinib in combination with temsirolimus in patients with human epidermal 
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growth factor receptor 2-dependent and other solid tumors (Gandhi et al., 2014), and called 
for more frequent use of novel designs. Wages et al. (2015) added to the discussion of 
Riviere et al. (2015) by describing the current implementation of novel methods in several 
ongoing early-phase combination studies, two of which are described below as motivating 
examples.
The limited use of innovative approaches in practice has lead to a recent push to introduce 
simpler methods centered on toxicity probability intervals, with the aim of greater feasibility 
and likelihood of being implemented. In the single-agent setting, Ivanova et al (2007) 
proposed the cumulative cohort design, which was extended to ordinal and continuous 
outcomes by Ivanova and Kim (2009). Ji et al.(2010) developed the modified toxicity 
probability interval (mTPI) design and, more recently, Liu and Yuan (2015) introduced the 
Bayesian optimal interval (BOIN) method. In the multi-agent setting, Mander and Sweeting 
(2015) proposed a curve-free method that relies on the product of independent beta 
probabilities, similar to the mTPI. This method aims to identify several combinations that 
form a maximum tolerated contour. The BOIN method has recently been extended to the 
combination setting by Lin and Yin (2015). In this paper, our objective is to shed some light 
on BOIN for combinations and compare it to some existing approaches that have been 
recently implemented in practice, within the context of real trial examples. Clinical trial 
design specifications, such as cohort size, skipping restrictions, stopping rules, etc., can be 
application (i.e. protocol/design) specific, and can therefore be difficult to generalize to all 
practical situations. In this paper, two of the designs discussed have been implemented in 
published/ongoing studies, so we illustrate them using the specifications utilized in practice. 
In the next section, we discuss some of the challenges associated with designing phase I 
combination studies. In Sections 3 – 5, we review three practical multi-agent dose-finding 
methods. In Section 6, we conduct simulations in order to illustrate the methods in a single 
trial, as well as to assess their performance over many trials. Finally, we conclude with some 
discussion.
2 General considerations in combination dose-finding
In general, we consider two-agent combination trials to be testing agents A and B with dose 
levels i = 1, …, I for A and j = 1, …, J for B, resulting in a I × J dose combination matrix. 
Let dij denote the combination consisting of dose level i of agent A and dose level j of agent 
B. Denote the probability of dose-limiting toxicity (DLT) at dij with πij and the target 
toxicity rate specified by physicians by ϕ. A key assumption to phase I methods for single-
agent trials is the monotonicity of the dose-toxicity curve. In this case, the curve is said to 
follow a “simple order” because the ordering of DLT probabilities for any pair of doses is 
known and administration of greater doses of the agent can be expected to produce DLT's in 
increasing proportions of patients. In studies testing combinations, the probabilities of DLT 
often follow a “partial order” (Barlow et al, 1972) in that there are pairs of combinations for 
which the ordering of the probabilities is not known.
The monotonicity assumption lends itself to escalation along a single line of doses. Given 
the toxicity response (DLT; yes/no) for a particular patient, we either recommend the same 
dose for the next patient or move to one of two adjacent doses (i.e. either escalate one dose 
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higher or de-escalate to one dose lower). In a multi-agent trial, there will most likely be 
more than one possible treatment on which to enroll the next patient cohort in a decision of 
escalation, which implies a set, ℰ, of “possible escalation combinations.” As an illustration, 
consider the 3 × 3 matrix in Figure 1. Suppose the first cohort receives combination d11 and 
no DLT's are observed. If d11 is well-tolerated, it is not clear which dose pair should be 
assigned to the next cohort of patients. The set of possible escalation combinations for d11 
would then consist of two combinations ℰ={d12, d21}. As demonstrated in Figure 1, there 
are several directions in which the trial could move in deciding which combination the next 
entered cohort should receive. Because we make the assumption that each drug has been 
carefully investigated before being combined, we assume that the probability of DLT for 
each drug increases monotonically when the dose of the other drug is being held fixed (i.e. 
across rows and up columns of the matrix of drug combinations). It may be clear that dose 
d12 is more toxic than d11, but, in the off-diagonal direction, we may not know the ordering 
between d12 and d21 because we increased the dose of A and decreased the dose of B. In 
terms of DLT probability, the conditions π11 < π12 and π11 < π21 may hold without it being 
possible to order π21 and π12 with respect to one another. It could be that π12 < π21 or π12 > 
π21.
2.1 Assumption of a single ordering
A traditional approach to this problem is to pre-select combinations with a known toxicity 
order, and apply a single-agent design by escalating and de-escalating along a chosen path. 
This could be done by, a priori, pre-specifying a subset of combinations for which we know 
the toxicity ordering. For instance, in the 3 × 3 grid in Figure 1, a selected subset of 
combinations that satisfies the monotonicity assumption is given by
This approach transforms the two-dimensional dose-finding space into a one-dimensional 
space, and was the approach taken in much of the early early work in combinations. Korn 
and Simon (1993) present a graphical method, called the “tolerable dose diagram,” based on 
single agent toxicity profiles, for guiding the escalation strategy in combination. Kramar, 
Lebecq and Candahl (1999) also lay out an a priori ordering for the combinations, and 
estimate the MTDC using a parametric model for the probability of a DLT as a function of 
the doses of the two agents in combination. The disadvantage of this approach is that it 
limits the number of combinations that can be considered and it can potentially miss 
promising dose combinations located outside of the path.
2.2 Specifying a small set of possible orderings
Rather than work with a single ordering, another approach to dealing with added complexity 
is to specify multiple possible orderings and appeal to established model selection 
techniques. Taking into account known and unknown relationships between combinations 
using the assumption of monotonicity up columns and across rows of the matrix, this 
approach proceeds by laying out multiple possible simple orders of the dose-toxicity 
relationship. For instance, for the 3 × 3 grid in Figure 1, two possible orderings of the DLT 
probabilities, πij, are
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Two methods making use of this approach are the Conaway, Dunbar, and Peddada (CDP) 
design (Conaway et al., 2004) and Wages, Conaway and O'Quigley (POCRM, 2011a,b), 
which are described in detail in subsequent sections.
2.3 Use of more fully parameterized models
The CDP design and POCRM both take an “underparameterized” approach, and, in the case 
of POCRM, rely upon several single parameter models from a CRM class of models 
(O'Quigley et al., 1990). Additional parameters can be utilized to further increase flexibility 
and account for possible interactive effects the two agents may have on the DLT 
probabilities. Thall et al. (2003) proposed a six-parameter model for the DLT probabilities 
of the dose combinations in order to identify a toxicity equivalence contour. Wang and 
Ivanova (2005) proposed a logistic-type regression for combinations that used the doses of 
the two agents as the covariates. Yin and Yuan (2009a,b) developed a Bayesian adaptive 
design based on latent 2 × 2 tables (2009a) and a copula-type model (2009b) for two agents. 
Braun and Wang (2010) proposed a hierarchical Bayesian model for the probability of 
toxicity at each combination. Hirakawa et al. (2013) proposed a dose-finding method based 
on the shrunken predictive probability of toxicity for the two agents. Baily et al. (2009) and 
Riviere et al. (2014) outlined Bayesian dose-finding procedures employing a logistic model. 
Jin et al. (2015) described using Bayesian model averaging over several candidate models, 
including a logistic model, a log-linear model, a Clayton-type copula (Clayton, 1978) model, 
and the six-parameter model of Thall et al. (2003). The added mathematical complexity in 
using more flexible models may hinder the implementation of these methods in practice. 
Estimation of the model parameters can be unstable due to the limited sample sizes observed 
in early-phase studies.
The review of Riviere et al. (2015) concluded that these approaches are not being employed 
in practice, with very few of the trials described by the authors implementing a novel 
approach. Most used some form of the one-dimensional approach described above in 
Section 2.1. This argues for the development of more simple approaches, provided they 
perform as well, or nearly as well, as methods that attempt to fully model the drug 
combination surface. Simulation results in recent publications (Wages, 2015; Hirakawa et 
al., 2015; Yin and Lin, 2015) demonstrate the strong performance of under-parameterized 
approaches, relative to more fully-parameterized approaches. In this article, we compare 
performance of three methods - (1) the CDP design, (2) POCRM, and (3) the BOIN method 
for combinations - based on 6 evaluation indices under 12 true combination-toxicity 
scenarios. In general, our goal is to evaluate (1) how well each method identifies MTDC's at 
and around the target rate, and (2) how well each method allocates patients to combinations 
at and around the target rate. We also provide a brief discussion of how feasible it is to 
implement each method given its respective design specifications and software capabilities.
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3 Conaway, Dunbar, Peddada (CDP) design
3.1 Phase I trial example using CDP method
A phase I, single-institution, investigator-initiated trial was designed and conducted to study 
induction therapy with VELCADE and Vorinostat in patients with surgically resectable non-
small cell lung cancer (NSCLC) (Jones et al., 2012). The primary objective of the study was 
to determine the MTDC of 3 doses (1.0, 1.3, 1.6 mg/m2) of VELCADE and 4 doses (100, 
200, 400, 600 mg) of Vorinostat in patients with NSCLC. The two-staged design of 
Conaway et al. (CDP; 2004) was used to estimate the MTDC of the 12 (3 × 4) drug 
combinations. The target toxicity rate for determining the MTD combination was 33%.
3.2 CDP estimation procedure
The CDP design is based on the estimation procedure of Hwang and Peddada (1994), which 
discusses parameter estimation subject to order restrictions. The procedure uses different 
estimation procedures for “nodal” and “non-nodal” parameters. A nodal parameter is one 
whose ordering is known with respect to all other parameters. For example, in a I × J matrix 
of drug combinations, the probability of DLT, π11, at combination d11 is a nodal parameter 
because it is known that π11 < πi+1,j and π11 < πi,j+1 for i, j ≥ 1. For nodal parameters, 
estimation proceeds by establishing a simple order that is consistent with the partial order. 
This is done by guessing the unknown inequalities, and obtaining isotonic regression 
estimates of the nodal parameters πij based on the Pool Adjacent Violators Algorithm 
(PAVA; Barlow et al., 1972). In order to estimate the non-nodal parameters, Hwang and 
Peddada (1994) eliminate the smallest number of parameters that make a non-nodal 
parameter into a nodal parameter. For instance, π12 is a non-nodal parameter because it is 
unknown whether π12 < π21 or vice versa. Estimates of the non-nodal parameters can be 
obtained using a version of PAVA for simple orders that fixes the nodal parameters at their 
previously estimated values. Hwang and Peddada (1994) show that the resulting estimates 
satisfy the partial order. The CDP design computed estimates of the parameters under all 
possible guesses and averaged them in order to eliminate the dependence of the estimates on 
a single guess at the ordering between non-nodal parameters.
The CDP method is a two-stage design. The initial stage is designed to quickly escalate 
through treatment combinations that are non-toxic (in single patient cohorts until first DLT 
is observed) and the second stage implements the Hwang and Peddada (1994) estimates. 
Throughout the second stage, the toxic response data for combination dij is of the form Y = 
{yij; i = 1, …, I; j = 1, …, J} with yij equal to the number of observed toxicities from patients 
treated with combination dij. Let  denote the set of treatments that have been administered 
thus far in the trial such that  = {dij : nij > 0}, where nij denotes the number of patients 
treated on each combination. Using a Beta(αij, βij) prior for the πij, the updated DLT 
probabilities, only for dij ∈ , are given by
Wages et al. Page 5
J Biopharm Stat. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
The estimation procedure of Hwang and Peddada (1994) is applied to the updated posterior 
means π̂ij for dij ∈ .
3.3 CDP design specifications
If appropriate prior information is available to investigators, it is described through a prior 
distribution of the form πij ~ Beta(αij, βij). The investigators specify the expected value of πij 
and an upper limit uij such that they are 95% certain that the toxicity probability will not 
exceed uij. The equations,
are solved in order to obtain prior specifications for αij and βij. Another prior specification 
for the CDP method is to choose a subset of possible dose-toxicity orders based on ordering 
the combinations by rows, columns, and diagonals of the drug combination matrix. Using 
the guidance of Wages and Conaway (2013), we choose a subset of approximately 6–9 
orderings. This provides an appropriate balance between choosing enough orderings so that 
we include adequate information to account for the uncertainty surrounding partially ordered 
dose-toxicity curves, without increasing the dimension of the problem so much so that we 
diminish performance. Arrange the orderings according to movements across rows, up 
columns and along diagonals. Since, in a large matrix, there could many ways to arrange 
combinations along a diagonal, we restrict movements to only moving across rows, up 
columns, and up or down any diagonal. For instance, in the 3 × 3 grid in Figure 1, six 
orderings arranged in this manner are given by:
1. across rows:
2. up columns:
3. up diagonals:
4. down diagonals:
5. down-up diagonals:
6. up-down diagonals:
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3.4 CDP dose-finding algorithm
Stage 1—The first patient is entered at the lowest combination d11. In the CDP method, the 
possible escalation combinations are defined as
so that ℰ = {neighboring combinations for which we know we are escalating}. For instance, 
if combination d11 is deemed safe, then the next cohort is treated with a combination chosen 
from among ℰ = {d21, d12}. If ℰ contains multiple combinations, the next cohort is 
randomized to a combination in the set. Once a DLT is observed, Stage 2 begins.
Stage 2—For all dij ∈ , we compute the loss, L(π̂ij, ϕ), associated with each 
combination. In this paper, as in the CDP design, we implement a symmetric loss function 
so that L(π̂ij, ϕ) = |π̂ij − ϕ|.
1.
Let , and let  be the set of combinations with losses equal to 
the minimum observed loss,  = {dij : Lij(π̂ij, ϕ) = lmin}.
2. If there is a single combination, dij ∈ , then the suggested combination is dij, with 
an estimated DLT probability of π̂ij
3. If  contains more than one combination, then we randomly choose from among 
them according to the rules:
a. If π̂ij > ϕ ∀ dij ∈ , we randomly choose from among the set  of candidate 
combinations.
b. If π̂ij ≤ ϕ for at least one dij ∈ , we choose randomly among the 
combinations in  that are candidate for having the “largest” DLT 
probability.
4. If the suggested combination has an estimated DLT probability that is less than the 
target, a combination is chosen at random from ℰ that have not yet been tested in 
the trial.
5. The MTDC is defined as di*j* such that
where  = {(dij : nij > 0} is the set of tried combinations.
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4 Partial order continual reassessment method (POCRM)
4.1 Phase I trial example 1 using POCRM
A dose escalation study was designed to determine the MTD / appropriate phase II dose 
combination of two small molecule inhibitors for refractory solid tumors and untreated 
metastatic disease. Agent A contained three doses (1.0, 1.5, 2.0 mg/day) and Agent B 
contained three doses (1000, 1250, 1500 mg/day), for a total of 9 (3 ×3) drug combinations. 
This FDA/IRB approved trial was designed using the two-stage POCRM (Wages et al., 
2011b). Each stage treated patients in single patient cohorts, and the target toxicity rate for 
determining the MTD combination was 30%.
4.2 Phase I trial example 2 using POCRM
A phase I trial was designed to determine the MTD of a combination of long peptides plus a 
toll-like receptor (TLR) agonists with or without a form of incomplete Freund's adjuvant 
(IFA) for the treatment of melanoma (NCT01585350). In this FDA/IRB approved trial, TLR 
agonists had 4 dose levels (25, 100, 400, 1600 EU) and IFA had three subgroups: 0 - IFA is 
not administered with any vaccine, V1 - IFA is administered with just the first vaccine, and 
V6 - IFA is administered in all vaccines. This trial was also designed using the two-stage 
POCRM (Wages et al., 2011b) There are a total of 12 combinations under consideration, and 
the target rate for determining the MTD combination was 33%.
4.3 POCRM estimation procedure
The CRM for partial orders is based on utilizing a class of working models that correspond 
to possible orderings of the toxicity probabilities for the combinations. Specifically, suppose 
there are M possible orderings being considered which are indexed by m. For a particular 
ordering, we model the true probability of toxicity, πij, corresponding to combination dij, via 
a power model
where the αij(m) represent the skeleton of the model under ordering m. In work done by 
Wages, the use of other single-parameter working models common to the CRM class, such 
as a hyperbolic tangent function or a one-parameter logistic model, was explored and found 
that there is little difference in the operating characteristics among the various model 
choices. We let the plausibility of each ordering under consideration be described by a set of 
prior weights τ = {τ(1), …, τ(M)}, where τ(m) ≥ 0 and ∑τ(m) = 1;m = 1, …, M. Using the 
accumulated data, Ωi, from i patients, the MLE âm of the parameter am can be computed for 
each of the m orderings, along with the value of the log-likelihood, ℒm(âm | Ωi), at âm. 
Wages et al. (2011b) proposes an escalation method that first chooses the ordering that 
maximizes the updated model weight
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before each patient inclusion. If we denote this ordering by m*, the authors use the estimate 
âm* to estimate the toxicity probabilities for each combination under ordering m* so that π̂ij 
≈ ψm*(dij, âm*).
4.4 POCRM design specifications
As in the CDP design, a prior specification for POCRM is to choose a subset of possible 
dose-toxicity orders. We again rely on the guidance of Wages and Conaway (2013) and 
choose approximately 6–9 orderings based on ordering the combinations by rows, columns, 
and diagonals of the drug combination matrix. Another specification that needs to be made 
prior to beginning the study is a set of skeleton values αij(m). We utilize the algorithm of 
Lee and Cheung (2009) to generate reasonable skeleton values using the function getprior 
in R package dfcrm. We simply need to specify skeleton values at each combination that 
are adequately spaced (O'Quigley and Zohar, 2010), and adjust them to correspond to each 
of the possible orderings, in order for POCRM to have good performance in terms of 
identifying an MTDC. The location of these skeleton values can be adjusted to correspond to 
each of the possible orderings using the getwm function in R package pocrm (Wages and 
Varhegyi, 2013).
4.5 POCRM dose-finding algorithm
Within the framework of sequential likelihood estimation, an initial escalation scheme is 
needed, since the likelihood fails to have a solution on the interior of the parameter space 
unless some heterogeneity (i.e. at least one DLT and one non-DLT) in the responses has 
been observed.
Stage 1—In our comparative study, in attempt to make the methods as comparable as 
possible, the initial escalation stage utilized in POCRM simulations is the same as that of the 
CDP design, where allocation is guided according to ℰ = {(i + 1, j), (i, j + 1)}.
Stage 2—Subsequent to a DLT being observed, the second stage of the trial begins.
1. Based on the accumulated data from i patients Ωi, the estimated toxicity 
probabilities π̂ij are obtained for all combinations being tested, based on the 
procedure described above.
2. The next entered patient is then allocated to the dose combination with estimated 
toxicity probability closest to the target rate so that |π̂ij − ϕ| is minimized.
3. There is no formal skipping restriction placed on model-based allocation in the 
POCRM method. That is, movement within the matrix is not restricted to a 
neighbor of the currently occupied combination in Stage 2. This is meant to allow 
for adequate exploration of the drug combination space. For instance, movement 
from d13 to d31 “skips” over d22, yet it is unknown whether this move is actually an 
escalation or a de-escalation due to the partial order, so we allow such a move to 
encourage experimentation throughout the matrix and to avoid getting “stuck” in 
certain regions of the space.
4. The MTDC is defined as di*j* such that
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after a total sample size of n patients.
5 Bayesian optimal interval (BOIN) design
5.1 BOIN estimation procedure
The BOIN method allocates patients to combinations based on lower and upper cut-off 
values, denoted ΔL > 0 and ΔU > 0, such that 0 < ϕ − ΔL < ϕ + ΔU < 1. Optimal values of ΔL 
and ΔU are given by
where ϕ1 is the highest DLT probability that is regarded as sub-therapeutic indicating 
escalation should be considered and ϕ2 (> ϕ1) is the lowest DLT probability that is regarded 
as too toxic indicating that de-escalation should be considered. Detailed derivations of ΔL 
and ΔU are provided in Lin and Yin (2015). Suppose the current cohort of patients is treated 
at dij, and let π̂ij = yij/nij be the estimated DLT rate, where yij is the number of observed 
DLT's and nij is the number of patients treated at dij. Based on the data from the current 
cohort, possible sets, ℰ and , for escalation and de-escalation, respectively, consist of row 
and column neighbors to the current combination.
5.2 BOIN design specifications
In practical situations, given a target rate of ϕ, the specifications of ϕ1 ∈ [0.5ϕ, 0.7ϕ] and ϕ2 
∈ [1.3ϕ, 1.5ϕ] are appropriate and yield good operating characteristics. The default values 
recommended by the authors of the BOIN method, both in single- (Liu and Yuan, 2015) and 
multiple-agents (Lin and Yin, 2015), are ϕ1 = 0.6ϕ and ϕ2 = 1.4ϕ. The prior distribution on 
each πij is Beta(0.5, 0.5).
5.3 BOIN allocation algorithm
The BOIN method for combinations allocates patient cohorts according to the following 
dose-finding algorithm.
1. Allocate the first cohort of patients to the lowest dose of each drug, i.e. 
combination d11
2. Based on the treatment of the current cohort at combination dij
a. If πîj ≤ ϕ − ΔL, escalate to the combination in ℰ that maximizes Pr{πi′j′ ∈ (ϕ 
− ΔL, ϕ + ΔU)| yi′j′}
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b. If π̂ij ≥ ϕ + ΔU, de-escalate to the combination in  that maximizes Pr{πi′j′ ∈ 
(ϕ − ΔL, ϕ + ΔU)| yi′j′}
c. Otherwise, if ϕ − ΔL < π̂ij < ϕ + ΔU, stay at the current combination dij
3. Continue this allocation procedure until the maximum sample size is reached.
During the allocation algorithm, if more than one combination is contained in ℰ or , the 
method randomly chooses one with equal probability. If no combinations are contained in ℰ 
and , the current combination is retained. On the boundary of the combination space, if i = 
1 and π̂ij ≥ ϕ + ΔU, the next combination is di,j−1, unless dij = d11 in which case the 
combination would remain d11. If i = I and πîj ≤ ϕ − ΔL, the next combination is di,j+1, 
unless dij = dIJ in which case the combination would remain dIJ. Similar allocations can be 
made with respect to the boundaries of j. After accrual of the maximum sample size into the 
study, estimates of the DLT rates, π̃ij, at each combinations are generated using bivariate 
isotonic regression (Barlow et al., 1972). The MTD combination di*,j* that is selected at the 
conclusion of the trial is that with the estimated DLT rate closest to the target rate so that
where  = {(dij : nij > 0} is the set of tried combinations.
6 Numerical studies
6.1 Simulation settings
We compared the operating characteristics among the three methods by simulating 2000 
trials under 12 scenarios with 3 × 3, 3 × 4, and 4 × 3 dose combination matrices with 
varying positions and number of true MTDCs, as shown in Table 1. These matrices, as well 
the simulation specifications (target rate ϕ, sample size n, etc.), correspond to the trial 
examples described in the previous sections. The target rate is set to ϕ = 0.30 in Scenarios 
1–4, ϕ = 0.33 in Scenarios 5–8, and ϕ = 0.20 in Scenarios 9–12. The sample size is n = 27 in 
Scenarios 1–4, n = 36 in Scenarios 5–8, and n = 36 in Scenarios 9–12. Throughout the 
simulations studies, for each method, a cohort of size 1 is used. In practice, patients can 
sometimes be treated in larger cohort sizes (i.e. 3), but since the POCRM and CDP methods 
were implemented in practical situations using smaller cohorts, we decided to illustrate 
performance using this specification. This was also aided by the fact that the R code for the 
BOIN method allowed the cohort size to be specified by the user, so we thought the most 
justifiable comparison would involve making it the same as the other methods. The true 
scenarios were used in designing the trial and obtaining approval of scientific review 
committees; IRBs and the FDA. In each scenario, an acceptable MTDC is defined as any 
combination with a true DLT probability within 5% of the target rate; (i.e. ϕ ± 0.05). An 
overdose combination is defined as any combination with true DLT probability larger than 
5% above the target rate; (i.e. > ϕ + 0.05).
For the CDP design, we present results for a prior that sets the prior mean equal to the target 
rate. We take the prior mean to equal ϕ, and a prior upper 95% limit of 0.70 for all 
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combinations. We utilized six possible orderings in all scenarios, arranging the combinations 
across rows, up columns, and up or down any diagonal. For POCRM, we utilized the same 
set of possible orderings as the CDP design. A uniform prior, τ, was placed on the orderings. 
The skeleton values, αij(m), were generated according to the algorithm of Lee and Cheung 
(2009) using the getprior function in R package dfcrm. Specifically, for 3 × 3 
combinations, we used getprior(0.05,0.30,4,9); for 3 × 4 combinations, we used 
getprior(0.05,0.33,6,12); and for 4 × 3 combinations, we used getprior(0.04,0.20,6,12). All 
simulation results were carried out using the functions of pocrm. For the BOIN method, we 
used the default values ϕ1 = 0.6ϕ and ϕ2 = 1.4ϕ and Beta(0.5, 0.5) prior for the DLT 
probability at each combination. The boundaries for the BOIN method are ϕ − ΔL ≈ 0.236, 
ϕ + ΔU ≈ 0.359 for Scenarios 1–4, ϕ − ΔL ≈ 0.263, ϕ + ΔU ≈ 0.398 for Scenarios 5–8, and 
ϕ − ΔL ≈ 0.157, ϕ + ΔU ≈ 0.238 for Scenarios 9–12.
6.2 Single trial illustration
In the simulation of DLT outcomes in a trial, the tolerance of each patient can be considered 
a uniformly distributed random variable on the interval [0, 1], which we term a patient's 
latent toxicity tolerance and denote uk for the kth entered patient (O'Quigley, Paoletti, 
Maccario, 2002). At the combination (dij) assigned to patient k, if the tolerance is less than 
or equal to its true DLT probability (i.e. uk ≤ πij), then patient k has a DLT; otherwise the 
patient has a non-DLT outcome. Of course, in a real trial, it is impossible to observe a 
patient's latent tolerance, but it is a useful tool in simulation and can be used to compare the 
operating characteristics of different designs within a single trial. Based on the same latent 
tolerance sequence, the allocation algorithms of the BOIN method, the CDP method, and 
POCRM can be evaluated using the same patients, although each patient will not be 
necessarily treated at the same combination with each method.
In conducting this exercise to compare the three methods discussed in this paper, we 
generated the latent tolerance sequence in Table 2 for n = 27 patients using the function 
runif(27) in R. The allocation algorithm is illustrated using the true DLT probabilities in 
Scenario 3 from Table 1, with target rate ϕ = 0.30. Each method begins on the lowest 
combination so that patient 1 receives d11. Because the tolerance u1 = 0.9776, he/she does 
not have a DLT, since u1 > 0.02. Escalating in cohorts of size 1, each method then 
recommends that the second patient receive one of two combinations in the set ℰ = {d12, 
d21}. The BOIN method and the CDP method randomize the second patient to d12, whereas 
POCRM randomizes to d21. The latent tolerance u2 = 0.5949 is larger than both π12 = 0.20 
and π21 = 0.06, resulting in a non-DLT outcome for each method. The first DLT occurs for 
each method at the 4th entered patient, based on a latent tolerance of u4 = 0.055, which is 
less than the true DLT probability for the combination recommended to this patient by each 
method. Notice at this point, both the CDP method and POCRM would terminate Stage 1 of 
their designs due to heterogeneity in the DLT outcomes, and proceed with their respective 
Stage 2. The BOIN method is a single stage design and thus proceeds in the same manner 
throughout the trial.
There are some interesting features to each design as it sequentially allocates. For this 
particular latent tolerance sequence, the algorithm of the CDP method appears to settle on 
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d22 very quickly (i.e. after patient 5), while POCRM and the BOIN method move around the 
drug combination space more. For this tolerance sequence, given this scenario, this is a very 
attractive feature for the CDP design, because it treats 23 of 27 patients, and ultimately 
recommends as the MTDC, d22, which has a true DLT probability of π22 = 0.33. However, 
this is only one simulated trial for a single latent sequence. Quickly settling on a 
combination can be a very good thing if that combination is an acceptable MTDC, but can 
be a poor design feature if the settled on combination is not an acceptable MTDC. Related to 
movement around the drug combination space, it is of interest to note that POCRM allows 
movement at both ends of a diagonal of the matrix. In other words, after patient 13 receives 
d13, the next combination recommended is d31. This represents a two dose level change in 
both agents, although it is unknown in practice whether this is actually an escalation or a de-
escalation. After n = 27 patients, POCRM recommends d13 as the MTDC, which has a true 
DLT probability of π13 = 0.33.
For the BOIN method, it is worth paying close attention to patients 22–24. Patient 22 
receives d22 and experiences DLT. At this point in the trial, π̂22 = y22/n22 = 2/9 ≈ 0.22. 
Since π̂22 < 0.236(ϕ−ΔL), the method recommends escalation to d32 after this DLT. Patient 
23 receives d32 and does not experience DLT. At this point in the trial, π̂32 = y32/n32 = 3/8 ≈ 
0.38. Since π̂32 > 0.358(ϕ + ΔU), the method recommends de-escalation to d23 after this non-
DLT. Thus, in this simulated trial, there are instances in which the BOIN method allows a 
de-escalation after non-DLT, as well as an escalation after a DLT. These recommendations 
appear to violate the principle of coherence, as defined by Cheung (2005). However, Liu and 
Yuan (2015) extended the coherence definition to include both short-term memory 
coherence and long-term memory coherence, and discussed the notion that long-term 
memory coherence is more practically relevant. Although the recommendations of patients 
23 and 24 violate short-term memory coherence, they obey long-term memory coherence, 
and, by this definition, can be considered justifiable allocations. At the conclusion of the 
trial, the BOIN method recommends d22 as the MTDC, which has a true DLT probability of 
π22 = 0.33. Each method recommends an acceptable MTDC in this simulated trial given the 
same latent toxicity sequence.
6.3 Evaluating performance over many situations
We assessed performance of the three methods based on 6 evaluation indices under 12 
toxicity scenarios. In general, our goal is to evaluate (1) how well each method locates 
MTDC's at and around the target rate (i.e. acceptable MTDC's), and (2) how well each 
method allocates patients to acceptable MTDC's. Of course, there will always be certain 
scenarios in which some methods perform better than others. Therefore, a useful tool in 
comparing dose-finding designs can be average performance over a broad range of 
scenarios. While traditional evaluation measures, such as the percentage of recommendation 
and allocation for true MTDC's are useful in assessing performance, it is also beneficial to 
consider the entire distribution of selected dose combination, as it provides more detailed 
information as to what combinations are being recommended if a true acceptable MTDC is 
missed. Cheung (2011) proposes to use the accuracy index, after n patients, defined as
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where πij is the true toxicity probability of dose combination dij and ρij is the probability of 
selecting dose combination dij as the MTDC. The maximum value of An is 1 with larger 
values (close to 1) indicating that the method possesses high accuracy.
6.4 Results
Figures 2 and 3 show the operating characteristics of the 3 methods under 12 scenarios. 
Across the 12 scenarios, the BOIN method, the CDP design and POCRM methods 
demonstrated averages of 47.4%, 43.0%, and 48.3% recommendation rates for true 
acceptable MTDCs, respectively. The BOIN design, the CDP design, and POCRM 
demonstrated averages of 26.7%, 23.7%, and 25.7% recommendation rates for overdose 
combinations, respectively. The average number of patients allocated to true acceptable 
MTDCs of the the BOIN method, the CDP design, and POCRM methods were averages of 
11.8, 11.3, and 12.7, respectively. The overall percentage of observed toxicities of the BOIN 
method, the CDP design, and POCRM methods were averages of 27.3%, 26.3%, and 25.7%, 
respectively. Although this percentage is lowest for POCRM, it is desirable for the value to 
be as close as possible to the target rate ϕ, which varies over the scenarios considered. 
Therefore, this overall percentage as a benchmark for performance is difficult to judge. In 
Scenarios 1–8, the BOIN method yields the average overall toxicity percentage closest to ϕ, 
whereas POCRM does so in Scenarios 9–12. Average number of patients allocated to a dose 
combination above the true MTDCs of the BOIN method, the CDP design, and POCRM 
methods were averages of 12.7, 11.23, and 9.92, respectively. Based on the accuracy index, 
the POCRM yielded a value of 0.583, the BOIN method produced a value of 0.576, and the 
CDP design resulted in a value of 0.564.
One of the most notable operating characteristics that should be taken away from these 
results occurs in Scenarios 2, 5, and 9 in which the only acceptable MTDC is the highest 
dose level of each agent, and thus is located at the top right corner of the drug combination 
matrix. In these cases, the CDP design struggles to select the highest combination relative to 
the other methods, and its performance in terms of recommending and allocating patients to 
acceptable MTDC's diminishes in these scenarios. For instance, in Scenario 2, the 
recommendation percentage of true acceptable MTDC's is 56.2% and 53.9% for the BOIN 
method and POCRM, respectively, where as this percentage is 34.1% for the CDP method. 
Scenarios 5 and 9 contain similar results, and these findings are also reflected in the 
accuracy index. In scenarios other than 2, 5, and 9, the CDP method performs very well, and 
is the best performing method, in terms of the evaluation metrics used, in five of the nine 
remaining scenarios (1, 3, 6, 8, and 11). This highlights the importance of average 
performance. The CDP method offers a higher risk-reward approach than the other two 
methods in terms of performance. If the true acceptable MTDC(s) are in the interior of the 
drug combination space, then the CDP method appears to be the best method, yielding the 
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highest performance in many scenarios. However, its drop-off in performance in the 
scenarios in which the true MTDC is at the top of the matrix makes the alternative methods 
more attractive options in these cases, and the overall average performance reflect the more 
consistent results of POCRM and the BOIN method. Overall, the results of these two 
methods are comparable, on average, across the scenarios considered.
7 Concluding remarks
Motivated by real life examples in phase I trial settings, we studied the operating 
characteristics of three simple dose-finding methods for combinations under various 
practical scenarios. We considered several scenarios in which there was no “perfect” 
MTDC; i.e. there are no combinations with true DLT rate exactly equal to the target toxicity 
rate. All three methods would be useful in the practical setting of phase I combination trials 
over designs employing a more complex model, because the design specifications are 
considerably less in the approaches considered here. Additionally, simulation studies in 
Wages (2015), Hirakawa et al. (2015), and Lin and Yin (2015) indicate that the performance 
in terms of recommending true MTDCs may diminish as the mathematical complexity of the 
method increases, given the small sample size constraints of phase I studies. As for 
implementation in practice, there is no available software for the CDP method, and its 
escalation algorithm can be difficult and time-consuming to program. POCRM has the 
advantage of directly building off of the well-known CRM and is likely to be more easily 
understood by clinicians and review boards. The POCRM has recently been extended to 
handle time-to-event outcomes (Wages, Conaway, and O'Quigley, 2013). In addition to the 
trial examples described in this work, The POCRM was implemented as part of a multi-site, 
phase I/II trial of combination immunotherapies that is currently open to enrollment at UVA 
and M.D. Anderson Cancer Center (NCT02126579; Wages, Slingluff, and Petroni, 2015). 
The estimation procedure employed by POCRM is used in this trial to adaptively monitor 
safety and to identify an acceptable set of regimens in high-risk melanoma patients. After 
each patient inclusion, POCRM updates the acceptable set of safe regimens, and the next 
patient is allocated to the acceptable regimen exhibiting the highest immunogenicity. Most 
recently, a bivariate extension of POCRM (Wages and Conaway, 2014) was implemented in 
a phase I/II design for a trial combining two small molecule inhibitors in relapsed/refractory 
mantle cell lymphoma. This pharmaceutical industry-sponsored trial has FDA approval, and 
is slated to open in mid-2015. Currently, POCRM is the only method described in this work 
that has available software on the web that can be used for design implementation (i.e. 
obtaining a combination recommendation for the next entered cohort, given the data to that 
point in the trial), as well as simulating design operating characteristics. R code for 
simulating the BOIN method is available upon request from the first author of their paper. 
The R code for the BOIN method provided the fastest simulation time among the three 
methods, but results for each method were able to be generated in a reasonable amount of 
time, making them all feasible for practical use.
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Figure 1. 
Illustration of a partial order between π11, π12 and π21 in a drug combination matrix. If d11 
is well tolerated, the set of possible escalation combinations is ℰ={d12, d21}. Two possible 
simple orders satisfy this partial order.
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Figure 2. 
Summary of the operating characteristics of the 3 methods in all scenarios.
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Figure 3. 
Summary of the operating characteristics of the 3 methods in all scenarios.
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